Clinical trials: HIV-1 Infection, open to volunteers
HIV Infection
Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)
In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral…
- Trial name
- MULTIVIR2025 (NCT06842706)
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hiv, HIV I Infection
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals.
- Trial name
- NCT06805656
- Testing
- Maraviroc, Dolutegravir, Dendritic Cell Vaccine
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo
HIV-1-infection
Efficacy and Safety of Doravirine in the Rapid Initiation
Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."
- Trial name
- RapiDO (NCT07357584)
- Testing
- Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet
- Where
- 2 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Fundación Huésped
HIV (Human Immunodeficiency Virus), HIV -1 Infection
Combining Latency Reversing Agents to Address the HIV Reservoir
The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which…
- Trial name
- PLUTO (NCT07384624)
- Testing
- Pyrimethamine (PYR), Lenalidomide, Topiramate (drug)
- Where
- 4 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
HIV -1 Infection
Analyses of Newly Diagnosed HIV Infection in Hong Kong
The goal of the project is to determine the epidemiologic status and changing patterns of HIV infection in Hong Kong. The main question it aims to answer is: what is the molecular pattern and burden of HIV-1 infections over the…
- Trial name
- NCT07725042
- Where
- Hong Kong
- Volunteers
- 720 people
- Sponsor
- Chinese University of Hong Kong
HIV-1-infection
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Protocol Number: FH-94 Study Objetives: Primary: To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed…
- Trial name
- PREDUAL (NCT07616739)
- Testing
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
- Where
- 10 sites in Argentina, Brazil
- Volunteers
- 210 people
- Sponsor
- Fundación Huésped
HIV Infections
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection.
- Trial name
- NCT07202546
- Testing
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 186 people
- Sponsor
- ViiV Healthcare
HIV-1, HIV Infection
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are…
- Trial name
- NCT07862569
- Testing
- DOR/ISL
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV I Infection, Tuberculosis
Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
- Trial name
- HVTN605A5421 (NCT05947890)
- Testing
- MTBVAC, BCG
- Where
- 16 sites in South Africa
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Depression, Anxiety, Trauma
Psychoeducation, Relaxation, PrOblem Solving, Activation, Cognitive Coping Therapy for Adolescents and Youth in HIV Care
The proposed PROACT study will test the effectiveness of a mental health intervention (psychotherapy) for multiple common mental health conditions (depressive, anxiety and trauma symptoms) among adolescents and youth with HIV in…
- Conditions
- Depression, Anxiety, Trauma, HIV-1-infection
- Trial name
- PROACT (NCT06247527)
- Testing
- Psychoeducation, Relaxation, PrOblem solving, Activation, Cognitive coping Therapy, Standard of care
- Where
- Kenya
- Volunteers
- 600 people
- Sponsor
- University of Nairobi
HIV Seropositivity, HIV Drug Resistance
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
- Conditions
- HIV Seropositivity, HIV Drug Resistance, HIV Infections
- Trial name
- PRINAVIH (NCT07146529)
- Volunteers
- 30,060 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Obesity, HIV-1-infection
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
The prevalence of obesity is rising worldwide, both in low- and high-income countries, including people with HIV (PWH). Semaglutide's efficacy in achieving weight loss in obese PWH is still unexplored.
- Trial name
- SWIFT (NCT04174755)
- Testing
- Semaglutide Injectable Product, Standard of care
- Where
- Ireland
- Volunteers
- 80 people
- Sponsor
- University College Dublin
HIV-1-infection
Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).
- Trial name
- NCT05143307
- Testing
- EBT-101
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Excision BioTherapeutics
HIV Infections
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA…
- Trial name
- NCT05674656
- Testing
- Dolutegravir/Rilpivirine FDC
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
HIV/AIDS
Dolutegravir Plus Lamivudine Simplified Therapy
Dolutegravir (DTG) is one type of integrase inhibitor, lamivudine (3TC) is one type of reverse transcriptase inhibitor, both of which are HIV medicine prevents HIV from self-multiplying, reduces the viral load.
- Trial name
- NCT03884673
- Testing
- DTG+ 3TC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV -1 Infection, Mental Health Issue
Integrating iSYV Within HIV Clinical Care for Youth Living With HIV in Tanzania
Youth living with HIV (YLWH) experience mental health (MH) challenges that compromise their HIV care. Though the MH gap is well described, MH service delivery to YLWH is rare, especially in low resource settings.
- Trial name
- NCT07621510
- Testing
- iSYV (integrated Sauti ya Vijana; The Voice of Youth), mHealth, eSOC
- Where
- Tanzania
- Volunteers
- 5,000 people
- Sponsor
- Duke University
HIV-1-infection
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
The goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in…
- Trial name
- NCT07683000
- Testing
- Lenacapavir, Lenacapavir Tablet, Teropavimab
- Where
- 2 sites in United States
- Volunteers
- 590 people
- Sponsor
- Gilead Sciences
HIV-1-infection
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
- Trial name
- ELDORADO (NCT06203132)
- Testing
- Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine
- Where
- 19 sites in Brazil, Cameroon and 4 more
- Volunteers
- 610 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, HIV-1-infection
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
Combination antiretroviral therapy (cART) blocks intracellular human immunodeficiency virus (HIV) replication in CD4+ T-lymphocytes, but fails to eliminate latent HIV infected CD4+ T-lymphocytes.
- Conditions
- HIV Infections, HIV-1-infection, HIV-2 Infection
- Trial name
- EX VIVO (NCT05215704)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Erasmus Medical Center
HIV
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
There is evidence that early and aggressive treatment with antiretroviral drugs can prevent the loss of immune cell function that accompanies HIV infection.
- Trial name
- NCT00039689
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)